HDAC3 represses the expression of NKG2D ligands ULBPs in epithelial tumour cells: potential implications for the immunosurveillance of cancer.
about
Targeting Epigenetic Processes in Photodynamic Therapy-Induced Anticancer ImmunityHDAC inhibitors and immunotherapy; a double edged sword?Pleiotropic Anti-Angiogenic and Anti-Oncogenic Activities of the Novel Mithralog Demycarosyl-3D-ß-D-Digitoxosyl-Mithramycin SK (EC-8042)The possible prognostic role of histone deacetylase and transforming growth factor β/Smad signaling in high grade gliomas treated by radio-chemotherapy: a preliminary immunohistochemical studySystems biology approaches to understanding Epithelial Mesenchymal Transition (EMT) in mucosal remodeling and signaling in asthmaTrichostatin A selectively suppresses the cold-induced transcription of the ZmDREB1 gene in maize.Synthesis and biological evaluation of triazol-4-ylphenyl-bearing histone deacetylase inhibitors as anticancer agentsLenalidomide induces immunomodulation in chronic lymphocytic leukemia and enhances antitumor immune responses mediated by NK and CD4 T cells.Sp1 transcription factor and GATA1 cis-acting elements modulate testis-specific expression of mouse cyclin A1Genetics, genomics, and evolutionary biology of NKG2D ligands.Overexpression of IL-32alpha increases natural killer cell-mediated killing through up-regulation of Fas and UL16-binding protein 2 (ULBP2) expression in human chronic myeloid leukemia cells.ZBP-89 reduces histone deacetylase 3 by degrading IkappaB in the presence of Pin1Modulation of NKG2D ligand expression and metastasis in tumors by spironolactone via RXRγ activation.Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinicPRL-3 mediates the protein maturation of ULBP2 by regulating the tyrosine phosphorylation of HSP60The inactive X chromosome is epigenetically unstable and transcriptionally labile in breast cancerRegulation of immune responses by histone deacetylase inhibitorsReversal of epigenetic silencing of MHC class I chain-related protein A and B improves immune recognition of Merkel cell carcinomaHistone deacetylase inhibitor, valproic acid, radiosensitizes the C6 glioma cell line in vitro.A Herpesviral induction of RAE-1 NKG2D ligand expression occurs through release of HDAC mediated repression.Synergistic enhancement of NK cell-mediated cytotoxicity by combination of histone deacetylase inhibitor and ionizing radiation.Cancer-germline antigen vaccines and epigenetic enhancers: future strategies for cancer treatment.The TGF-β-induced up-regulation of NKG2DLs requires AKT/GSK-3β-mediated stabilization of SP1.Mechanisms of tumor and viral immune escape from natural killer cell-mediated surveillance.Histone deacetylase inhibitors in the generation of the anti-tumour immune response.Targeting NKG2D in tumor surveillance.NKG2D signaling in cancer immunosurveillance.Molecular Bases for the Regulation of NKG2D Ligands in Cancer.γδ T cells as a potential tool in colon cancer immunotherapy.Upregulation of LYAR induces neuroblastoma cell proliferation and survival.How do tumor cells respond to HDAC inhibition?Methylation of NKG2D ligands contributes to immune system evasion in acute myeloid leukemia.Influence of Histone Deacetylase Inhibitors and DNA-Methyltransferase Inhibitors on the NK Cell-Mediated Lysis of Pediatric B-Lineage Leukemia.Drug-induced hyperploidy stimulates an antitumor NK cell response mediated by NKG2D and DNAM-1 receptors.Sensitizing primary acute lymphoblastic leukemia to natural killer cell recognition by induction of NKG2D ligands.Histone deacetylase inhibitors impair NK cell viability and effector functions through inhibition of activation and receptor expression.Innate Immune Recognition of Double-stranded RNA Triggers Increased Expression of NKG2D Ligands After Virus Infection.Regulation of NKG2D signaling during the epithelial-to-mesenchymal transition.Susceptibility to natural killer cell-mediated lysis of colon cancer cells is enhanced by treatment with epidermal growth factor receptor inhibitors through UL16-binding protein-1 induction.New prospects on the NKG2D/NKG2DL system for oncology.
P2860
Q26797280-7DB960EF-115A-4CEC-B0B9-802E68F2BBB7Q26853102-EF37686E-3F93-4E68-A0E0-A0FC942C0EB8Q28550699-31B9D72A-EDBD-4812-9B72-7A72BEA53D71Q33712267-2B629F08-8753-4F8E-AD32-4F31CF13DCD1Q33796731-49C986F0-AE5A-488D-8E67-1F6BCB123E2AQ33979693-0B8A44F6-821E-48E0-A5AE-1F11F866B36BQ34055631-724C0F3F-47A5-4F2E-B510-E695D2DEDFABQ34278096-69B0E929-CF63-4521-9160-EE0108BCB0A1Q34462360-82D8005D-DE9D-4C2D-921F-002C1F03B9BBQ34489980-97A8D675-375B-4551-9E37-3122E787D82EQ34752043-7BAC74D1-857E-4DDE-B797-87AA61B9A5DCQ35030172-A8841F0F-CCDC-4848-BBA3-2231DE0E144DQ35031677-D054190A-17BC-4365-AECA-9188B369815BQ35038016-44EEA685-204A-4704-8FCD-29221C1D83AEQ35163691-6D167EDD-EF24-41F1-AC91-06AA3F064E21Q35238263-FB768961-0CBB-49BB-A537-D891F17CC029Q35855571-5019A958-F962-4D50-B811-089633A3C880Q36605917-B052E08B-58BD-4D97-AE0B-E69B008D8CC8Q37388728-9B5FC611-7EA0-483E-BCC5-AF91B309471EQ37462652-14DA2DAD-D072-4606-A299-AC67D493DCAFQ37581705-4364F9E9-DF41-4C74-A439-FAC71578A270Q37737327-AE3F4445-BEB5-4084-99CE-DD97CCB1CA28Q37747352-C2220700-672E-4083-9313-5A044DBB2B19Q37876089-E10FC0CF-AC7F-4819-91FD-176E4BDAF21BQ37953826-3FDB5872-CF26-4C2C-B854-84F5CA7E6494Q38005176-B526F8DC-5AC9-4A7D-8DA0-BBAB062BF964Q38194944-D0A073AB-38D2-4252-A974-AAC2D355A636Q38202957-5A9BCB4E-83E9-4976-BD88-F512ED6C5A1AQ38262257-DC3FDE63-831C-40C7-96D9-1CB90AB37D01Q38689375-C22FD9B1-DAAA-4D2B-8BB0-BE2E17A8AE04Q38817005-E65BAE59-4152-4DF9-8BED-8DE66E81ECE9Q38940720-D91A0DA5-BABA-4979-8B49-B28B81A48259Q39156647-B2C6A601-18DB-47CF-8359-5A50503FE5C8Q39279504-347D308A-1EF7-409A-8489-FEA773A50EDCQ39323511-5B843100-FCB6-4714-8C0E-BD2034A76C28Q39436145-73798B33-5CDC-47AA-84BD-88F14B7909CCQ41922559-0549F5E4-0A3D-427F-9814-6E204084E2FAQ42092387-090FC24F-2CD2-432A-9D95-38424DC7F7D4Q42726557-D5397293-578F-499D-9B4D-7551F8049E7FQ42796257-A370EF51-AD58-4A39-93F4-7D3E501B2C95
P2860
HDAC3 represses the expression of NKG2D ligands ULBPs in epithelial tumour cells: potential implications for the immunosurveillance of cancer.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
HDAC3 represses the expression ...... immunosurveillance of cancer.
@en
HDAC3 represses the expression ...... immunosurveillance of cancer.
@nl
type
label
HDAC3 represses the expression ...... immunosurveillance of cancer.
@en
HDAC3 represses the expression ...... immunosurveillance of cancer.
@nl
prefLabel
HDAC3 represses the expression ...... immunosurveillance of cancer.
@en
HDAC3 represses the expression ...... immunosurveillance of cancer.
@nl
P2860
P356
P1433
P1476
HDAC3 represses the expression ...... e immunosurveillance of cancer
@en
P2093
P2860
P2888
P304
P356
10.1038/ONC.2009.117
P407
P577
2009-05-11T00:00:00Z